Drug intelligence / Profile preview

GSK4771261

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

GSK4771261 is an investigational monoclonal antibody developed by GSK for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is currently in Phase 1 clinical development. The drug is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with ADPKD. The precise molecular target and mechanism of action have not been publicly disclosed as of June 2025. This suggests that either a novel pathway relevant to ADPKD pathogenesis is being targeted or that the developer has chosen to keep these details confidential at this early stage[1][2][3][5].

Other names: GSK 4771261GSK4771261GSK-4771261

Targets

PAPPA (Pregnancy-associated plasma protein A)

Beyond the preview

Go deeper on GSK4771261.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK4771261.

Explore the full profile